文献速递胸部肿瘤

阿维鲁单抗治疗晚期不可切除间皮瘤患者的疗效与安全性:JAVELIN实体瘤试验1b期结果

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项1b期开放标签研究在25个中心纳入53例铂类和培美曲塞治疗后进展的不可切除间皮瘤患者,接受阿维鲁单抗10 mg/kg每2周一次治疗。确认客观缓解率为9%(5例,95%CI 3.1%-20.7%),中位缓解持续时间15.2个月,疾病控制率58%,中位无进展生存期4.1个月,中位总生存期10.7个月,安全性可接受。

要点

  • 铂类和培美曲塞治疗后进展的间皮瘤患者中,阿维鲁单抗确认客观缓解率为9%(5/53)。
  • 缓解持久,中位缓解持续时间15.2个月(95%CI 11.1至不可估计月)。
  • 5例(9%)发生3级或4级治疗相关不良事件,无治疗相关死亡。

核心结论

  • 在经重度治疗的间皮瘤队列中,阿维鲁单抗显示出持久的抗肿瘤活性和疾病控制,安全性可接受。

研究设计与样本

  • 1b期开放标签研究(JAVELIN实体瘤试验),于2014年9月9日至2015年7月22日在3个国家的25个中心入组。
  • 纳入53例铂类和培美曲塞治疗后进展的不可切除间皮瘤患者。
  • 干预为阿维鲁单抗10 mg/kg每2周一次,直至疾病进展、不可接受毒性或退出研究。

主要发现

  • 中位年龄67岁(范围32-84岁),男性32例(60%),20例(38%)既往接受过3线及以上治疗(中位2线,范围1-8线)。
  • 截至2016年12月31日,中位随访24.8个月(范围16.8-27.8个月)。
  • 确认客观缓解率为9%(5例;95%CI 3.1%-20.7%),其中完全缓解1例、部分缓解4例。
  • 中位缓解持续时间为15.2个月(95%CI 11.1至不可估计月);疾病控制率为58%(31例)。
  • 中位无进展生存期4.1个月(95%CI 1.4-6.2个月),12个月无进展生存率17.4%(95%CI 7.7%-30.4%);中位总生存期10.7个月(95%CI 6.4-20.2个月),12个月总生存率43.8%(95%CI 29.8%-57.0%)。

关键数值与推荐

  • 以5%为PD-L1表达 cutoff,PD-L1阳性肿瘤患者客观缓解率为19%(3/16;95%CI 4.0%-45.6%),PD-L1阴性肿瘤患者为7%(2/27;95%CI 0.9%-24.3%)。
  • 5例(9%)发生3级或4级治疗相关不良事件,3例(6%)发生3级或4级免疫相关、治疗相关不良事件;无治疗相关死亡。

临床怎么用

  • 作者认为,在经重度治疗的间皮瘤患者中,阿维鲁单抗显示出持久的抗肿瘤活性和疾病控制,安全性可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti-programmed cell death 1 (PD-1) antibodies have antitumor activity in this disease, but little is known about the activity of anti-programmed cell death ligand 1 (PD-L1) antibodies in patients with mesothelioma. OBJECTIVE: To assess the efficacy and safety of avelumab in a cohort of patients with previously treated mesothelioma. DESIGN, SETTING, AND PARTICIPANTS: Phase 1b open-label study (JAVELIN Solid Tumor) in patients with unresectable mesothelioma that progressed after platinum and pemetrexed treatment, enrolled at 25 sites in 3 countries between September 9, 2014, and July 22, 2015. INTERVENTIONS: Participants received avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study. MAIN OUTCOMES AND MEASURES: Prespecified end points included confirmed best overall response based on Response Evaluation Criteria In Solid Tumors, version 1.1; duration of response; progression-free survival (PFS); overall survival (OS); PD-L1 expression-based analyses; and safety. RESULTS: Of 53 patients treated with avelumab, the median age was 67 (range, 32-84) years; 32 (60%) were male. As of December 31, 2016, median follow-up was 24.8 (range, 16.8-27.8) months. Twenty patients (38%) had 3 or more previous lines of therapy (median, 2; range, 1-8). The confirmed objective response rate (ORR) was 9% (5 patients; 95% CI, 3.1%-20.7%), with complete response in 1 patient and partial response in 4 patients. Responses were durable (median, 15.2 months; 95% CI, 11.1 to not estimable months) and occurred in patients with PD-L1-positive tumors (3 of 16; ORR, 19%; 95% CI, 4.0%-45.6%) and PD-L1-negative tumors (2 of 27; ORR, 7%; 95% CI, 0.9%-24.3%) based on a 5% or greater PD-L1 cutoff. Disease control rate was 58% (31 patients). Median PFS was 4.1 (95% CI, 1.4-6.2) months, and the 12-month PFS rate was 17.4% (95% CI, 7.7%-30.4%). Median OS was 10.7 (95% CI, 6.4-20.2) months, and the median 12-month OS rate was 43.8% (95% CI, 29.8%-57.0%). Five patients (9%) had a grade 3 or 4 treatment-related adverse event, and 3 (6%) had a grade 3 or 4 immune-related, treatment-related adverse event. There were no treatment-related deaths. CONCLUSIONS AND RELEVANCE: Avelumab showed durable antitumor activity and disease control with an acceptable safety profile in a heavily pretreated cohort of patients with mesothelioma. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01772004.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019. PMID: 30605211. doi:10.1001/jamaoncol.2018.5428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。